对《针对美国国家标准与技术研究院标准参考物质1934的程序性死亡受体配体1免疫组化检测的定量比较》的勘误 - Suppr

Suppr

超能文献

Correction to: Quantitative comparison of PD-L1 IHC assays against NIST standard reference material 1934.

作者信息

Sompuram Seshi R, Torlakovic Emina E, 't Hart Nils A, Vani Kodela, Bogen Steven A

机构信息

Boston Cell Standards Inc., Boston, MA, USA.

University of Saskatchewan and Saskatoon Health Authority, Saskatoon, SK, Canada.

出版信息

Mod Pathol. 2021 Dec;34(12):2242. doi: 10.1038/s41379-021-00898-4.

DOI:10.1038/s41379-021-00898-4

PMID:34493826

Abstract

摘要

相似文献

Correction to: Quantitative comparison of PD-L1 IHC assays against NIST standard reference material 1934.

Mod Pathol. 2021 Dec;34(12):2242. doi: 10.1038/s41379-021-00898-4.

Quantitative comparison of PD-L1 IHC assays against NIST standard reference material 1934.

Mod Pathol. 2022 Mar;35(3):326-332. doi: 10.1038/s41379-021-00884-w. Epub 2021 Aug 13.

Paired Comparison of PD-L1 Expression on Cytologic and Histologic Specimens From Malignancies in the Lung Assessed With PD-L1 IHC 28-8pharmDx and PD-L1 IHC 22C3pharmDx.

Appl Immunohistochem Mol Morphol. 2017 Aug;25(7):453-459. doi: 10.1097/PAI.0000000000000540.

Comparison of PD-L1 tumor cell expression with 22C3, 28-8, and SP142 IHC assays across multiple tumor types.

J Immunother Cancer. 2022 Oct;10(10). doi: 10.1136/jitc-2022-005573.

PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project.

J Thorac Oncol. 2017 Feb;12(2):208-222. doi: 10.1016/j.jtho.2016.11.2228. Epub 2016 Nov 29.

Reliability of PD-L1 assays using small tissue samples compared with surgical specimens.

Medicine (Baltimore). 2019 Apr;98(14):e14972. doi: 10.1097/MD.0000000000014972.

A real-world, comparative study of FDA-approved diagnostic assays PD-L1 IHC 28-8 and 22C3 in lung cancer and other malignancies.

J Clin Pathol. 2018 Dec;71(12):1078-1083. doi: 10.1136/jclinpath-2018-205362. Epub 2018 Oct 1.

Harmonization across programmed death ligand 1 (PD-L1) assays for lung cancer by immunohistochemistry using noncontact alternating current electric field mixing.

Thorac Cancer. 2021 Apr;12(8):1187-1194. doi: 10.1111/1759-7714.13893. Epub 2021 Mar 2.

[Predictive PD-L1 immunohistochemistry for non-small cell lung cancer : Current state of the art and experiences of the first German harmonization study].

Pathologe. 2016 Nov;37(6):557-567. doi: 10.1007/s00292-016-0189-1.

PCR-based analysis of PD-L1 RNA expression in lung cancer: comparison with commonly used immunohistochemical assays.

Ann Diagn Pathol. 2022 Aug;59:151968. doi: 10.1016/j.anndiagpath.2022.151968. Epub 2022 May 6.

引用本文的文献

Digital spatial profiling of melanoma shows CD95 expression in immune cells is associated with resistance to immunotherapy.

Oncoimmunology. 2023 Sep 27;12(1):2260618. doi: 10.1080/2162402X.2023.2260618. eCollection 2023.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Correction to: Quantitative comparison of PD-L1 IHC assays against NIST standard reference material 1934.

作者信息

Sompuram Seshi R, Torlakovic Emina E, 't Hart Nils A, Vani Kodela, Bogen Steven A

机构信息

Boston Cell Standards Inc., Boston, MA, USA.

University of Saskatchewan and Saskatoon Health Authority, Saskatoon, SK, Canada.

出版信息

Mod Pathol. 2021 Dec;34(12):2242. doi: 10.1038/s41379-021-00898-4.

DOI:10.1038/s41379-021-00898-4

PMID:34493826

Abstract

摘要

相似文献

Correction to: Quantitative comparison of PD-L1 IHC assays against NIST standard reference material 1934.

Mod Pathol. 2021 Dec;34(12):2242. doi: 10.1038/s41379-021-00898-4.

Quantitative comparison of PD-L1 IHC assays against NIST standard reference material 1934.

Mod Pathol. 2022 Mar;35(3):326-332. doi: 10.1038/s41379-021-00884-w. Epub 2021 Aug 13.

Paired Comparison of PD-L1 Expression on Cytologic and Histologic Specimens From Malignancies in the Lung Assessed With PD-L1 IHC 28-8pharmDx and PD-L1 IHC 22C3pharmDx.

Appl Immunohistochem Mol Morphol. 2017 Aug;25(7):453-459. doi: 10.1097/PAI.0000000000000540.

Comparison of PD-L1 tumor cell expression with 22C3, 28-8, and SP142 IHC assays across multiple tumor types.

J Immunother Cancer. 2022 Oct;10(10). doi: 10.1136/jitc-2022-005573.

PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project.

J Thorac Oncol. 2017 Feb;12(2):208-222. doi: 10.1016/j.jtho.2016.11.2228. Epub 2016 Nov 29.

Reliability of PD-L1 assays using small tissue samples compared with surgical specimens.

Medicine (Baltimore). 2019 Apr;98(14):e14972. doi: 10.1097/MD.0000000000014972.

A real-world, comparative study of FDA-approved diagnostic assays PD-L1 IHC 28-8 and 22C3 in lung cancer and other malignancies.

J Clin Pathol. 2018 Dec;71(12):1078-1083. doi: 10.1136/jclinpath-2018-205362. Epub 2018 Oct 1.

Harmonization across programmed death ligand 1 (PD-L1) assays for lung cancer by immunohistochemistry using noncontact alternating current electric field mixing.

Thorac Cancer. 2021 Apr;12(8):1187-1194. doi: 10.1111/1759-7714.13893. Epub 2021 Mar 2.

[Predictive PD-L1 immunohistochemistry for non-small cell lung cancer : Current state of the art and experiences of the first German harmonization study].

Pathologe. 2016 Nov;37(6):557-567. doi: 10.1007/s00292-016-0189-1.

PCR-based analysis of PD-L1 RNA expression in lung cancer: comparison with commonly used immunohistochemical assays.

Ann Diagn Pathol. 2022 Aug;59:151968. doi: 10.1016/j.anndiagpath.2022.151968. Epub 2022 May 6.

引用本文的文献

Digital spatial profiling of melanoma shows CD95 expression in immune cells is associated with resistance to immunotherapy.

Oncoimmunology. 2023 Sep 27;12(1):2260618. doi: 10.1080/2162402X.2023.2260618. eCollection 2023.